'WBC probe into boxer Povetkin's doping case may take 2 months'

Image
IANS Moscow
Last Updated : May 28 2016 | 1:42 PM IST

The World Boxing Council (WBC) probe on Russian heavyweight boxer Alexander Povetkin, whose Sample A and B tested positive for banned substance meldonium, may take up to two months, Andrei Ryabinsky, the head of the Boxing World promotion company said.

WBC Heavyweight Champion Deontay Wilder of the United States (W36-L0, 35 KOs) was scheduled to hold his mandatory title bout against Povetkin (30-1, 22 KOs) on May 21 in Moscow, However, Russian boxer's doping Sample A had tested positive for meldonium shortly before the fight and the bout was suspended indefinitely. His Sample B also tested positive for the same substance.

"I personally believe that it [the investigation] will take a couple of months," Ryabinsky said in an interview with TASS on Friday.

Sample A revealed that the body system of the 36-year-old Russian fighter contained a low concentration of 0.07 micrograms. US sports channel ESPN later reported that before the positive doping result, Povetkin passed doping tests three times, namely on April, 7,8 and 11, and all his samples tested negative.

However, his doping test as of April 27 gave a positive indication for meldonium presence in his blood.

Wilder's management announced earlier it intended to demand from the Russian side a financial compensation of $4.6 million in case the bout was eventually cancelled.

The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete's blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).

However, on April 13, WADA announced that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.

Meldronate is a cardiovascular preparation freely available for purchase at pharmacies across Russia without doctor's prescription.

--IANS

pur/vm

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 28 2016 | 1:30 PM IST

Next Story